Ceftazidime
Cephalosporins
beta-Lactamases
Aztreonam
Microbial Sensitivity Tests
Pseudomonas aeruginosa
Thienamycins
beta-Lactams
Amikacin
Imipenem
Monobactams
Piperacillin
Klebsiella pneumoniae
Gram-Negative Bacteria
Penicillanic Acid
Melioidosis
Cefoperazone
Azabicyclo Compounds
beta-Lactam Resistance
Drug Resistance, Microbial
Enterobacteriaceae
Tobramycin
Burkholderia pseudomallei
Enterobacter cloacae
Bronchopneumonia
Clavulanic Acid
Gram-Negative Bacterial Infections
Moxalactam
Isoelectric Focusing
Serum Bactericidal Test
Drug Therapy, Combination
Carbapenems
Bacteria
Drug Resistance, Bacterial
Ceftriaxone
Half-Life
Lactams
Drug Resistance, Multiple, Bacterial
Escherichia coli
Sulbactam
Home Infusion Therapy
Enterobacter
Endophthalmitis
Klebsiella
Infusions, Intravenous
Penicillins
Gentamicins
Drug Incompatibility
Cefsulodin
Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. (1/736)
Treatment of septicemia caused by Escherichia coli with ceftazidime (CAZ) may be associated with the development of septic shock due to the release of bacterial lipopolysaccharide. We examined the suppressive effect of clindamycin (CLDM) on CAZ-induced release of endotoxin by cultured E. coli and the subsequent production of inflammatory cytokines (tumor necrosis factor alpha [TNF-alpha] and interleukin-1 beta [IL-1 beta]). E. coli ATCC 12014 was incubated in inactivated horse serum with or without CLDM for 1, 4, or 18 h, followed by the addition of CAZ and collection of the culture supernatant at 0, 1, and 2 h. The concentration of endotoxin in each sample was measured by a chromogenic Limulus test. Another portion of the culture supernatant was added to THP-1 cell culture and incubated for 4 h, and the concentrations of TNF-alpha and IL-1 beta in the supernatant were measured by an enzyme-linked immunosorbent assay. In the control group (no CLDM), CAZ administration resulted in significant increases in endotoxin, TNF-alpha, and IL-1 beta concentrations. Pretreatment of E. coli with CLDM for 4 or 18 h before the addition of CAZ significantly suppressed the concentrations of endotoxin, TNF-alpha, and IL-1 beta in a time-dependent manner. In addition, CAZ treatment transformed E. coli from rodshaped bacteria to filament-like structures, as determined by electron microscopy, while pretreatment with CLDM prevented these morphological changes. Our in vitro studies showed that CAZ-induced release of large quantities of endotoxin by E. coli could be suppressed by prior administration of CLDM. (+info)Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. (2/736)
DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis. (+info)Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. (3/736)
Several extended-spectrum beta-lactamases (ESBLs) belonging to molecular Class D have been described from Pseudomonas aeruginosa isolates collected in Turkey. Four of these, OXA-11, -14, -16 and -17, are derivatives of OXA-10 beta-lactamase. We tried to select similar mutants in vitro from OXA-10-producing transconjugants of P. aeruginosa, using a multistep method on ceftazidime-containing agars. Forty-four such mutants were obtained; all had increased resistance to ceftriaxone, cefsulodin, cefepime, cefpirome, latamoxef, aztreonam and, especially, ceftazidime whereas MICs of piperacillin, carbenicillin, cefotaxime, cefoperazone and carbapenems were little altered. Genes related to blaOXA-10 were sequenced from five mutants. One mutant enzyme had aspartate instead of glycine at position 157, and corresponded exactly to natural OXA-14 beta-lactamase. Another mutant strain appeared to have both OXA-14 and a new pI 6.2 enzyme, designated OXA-M102, with serine instead of alanine at position 124 and aspartate instead of glycine at position 157. This latter variant resembled natural OXA-16 enzyme, which has threonine at position 124 and aspartate at position 157. The remaining three mutant enzymes differed from any so far found in wild-type isolates. Two had leucine replacing tryptophan at position 154 (this enzyme was named OXA-M101) while the third (OXA-M103) had a pI of 7.6, and had lysine instead of asparagine at position 143. A different mutation at this position was previously found in OXA-11, a wild-type OXA-10 mutant. Thus, some of the ESBL mutants selected (OXA-14 and OXA-M102) correspond exactly or almost exactly to ESBLs found in wild-types, whereas others (OXA-M101 and OXA-M103) were totally new. (+info)Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. (4/736)
An open-label, randomized, comparative, multi-centre study was conducted at 25 centres in the USA and Canada to compare the safety and efficacy of piperacillin/tazobactam plus tobramycin with ceftazidime plus tobramycin in patients with lower respiratory tract infections. Piperacillin/tazobactam (3 g/375 mg) every 4 h or ceftazidime (2 g) every 8 h were administered i.v. for a minimum of 5 days. Tobramycin (5 mg/kg/day) given in divided doses every 8 h was administered to all patients. Patients with Pseudomonas aeruginosa isolated from respiratory secretions at baseline were to continue tobramycin for the duration of the study. Tobramycin could be discontinued in other patients after the baseline culture results were known. A total of 300 patients was randomized, 155 into the piperacillin/tazobactam group and 145 into the ceftazidime group. Of these, 136 patients (78 in the piperacillin/tazobactam group and 58 in the ceftazidime group) were considered clinically evaluable. Both groups were comparable for age, sex, duration of treatment and other demographic features. The clinical success rate in evaluable patients was significantly greater (P = 0.006) in the piperacillin/tazobactam treatment group (58/78; 74%) than in the ceftazidime group (29/58; 50%). Eradication of the baseline pathogen was significantly greater (P = 0.003) in the piperacillin/tazobactam group (66%) than in the ceftazidime group (38%). The clinical and bacteriological responses of those patients with nosocomial pneumonia were similar to the overall results. Twelve (7.7%) piperacillin/tazobactam-treated patients and 24 (17%) ceftazidime-treated patients died during the study (P = 0.03). Seven of the 24 deaths in the ceftazidime treatment group but only one of the 12 deaths in the piperacillin/tazobactam treatment group were directly related to failure to control infection. The majority of adverse events were thought by the investigator to be attributable to the patients' underlying disease and not drug related. In this study, piperacillin/tazobactam plus tobramycin was shown to be more effective and as safe as ceftazidime plus tobramycin in the treatment of patients with nosocomial LRTI. (+info)In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. (5/736)
A total of 3903 pathogens from 48 Canadian medical centres were tested against 19 antimicrobial agents. Five agents showed activity against > or = 90% of all 1982 respiratory tract pathogens tested (ciprofloxacin, 90%; cefoperazone, 91%; ticarcillin/clavulanate, 92%; ceftazidime and imipenem, 93% each). Nine agents had > or = 90% activity against Enterobacteriaceae from respiratory tract infection (cefotaxime and ticarcillin/clavulanate, 90% each; aztreonam, ceftizoxime and ceftriaxone, 91% each; ceftazidime, 93%; ciprofloxacin, 97%; imipenem and netilmicin, 98% each). Similarly, five agents had activity against > or = 90% of all 1921 urinary tract pathogens tested (ciprofloxacin and ticarcillin/clavulanate, 90% each; cefoperazone and netilmicin, 91% each; imipenem, 99%). Nine agents had > or = 95% activity against Enterobacteriaceae from urinary tract infection (ciprofloxacin, 95%; cefotetan, 97%; aztreonam, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone and netilmicin, 98% each; imipenem, 99%). Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%. (+info)Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. (6/736)
Several lower respiratory tract infection (LRTI) trials have documented a correlation between clinical response and area under the inhibitory curve (24 h AUC/MIC; AUIC). The AUIC values in these studies were based on measured MICs and measured serum concentrations. This study evaluates AUIC estimates made using population pharmacokinetic parameters, and MICs from an automated microbiological susceptibility testing system. A computer database review over 2 years yielded 81 patients at Millard Fillmore Hospital with a culture-documented gram-negative LRTI who had been treated with piperacillin and an aminoglycoside, ceftazidime, ciprofloxacin or imipenem. Their AUIC values were estimated using renal function, drug dosages and MIC values. Outcome groups (clinical and microbiological cures and failures) were related to the AUIC values using Kruskal-Wallis ANOVA, linear regression and classification and regression tree (CART) analysis. A significant breakpoint for clinical cures was an AUIC value at least 72 SIT(-1) x 24 h (inverse serum inhibitory titre integrated over time). All antibiotics performed significantly better above this value than below it. Clinical cure was well described by a Hill-type equation. Within the piperacillin/aminoglycoside regimen, most of the activity came from the piperacillin, which had a higher overall AUIC value than the aminoglycoside. AUIC estimations based upon MIC values derived from the automated susceptibility testing method differed from NCCLS breakpoint data and from tube dilution derived values in this hospital by as much as three tube dilutions. These automated methods probably overestimated the MIC values of extremely susceptible organisms. The lack of precise MIC estimates in automated clinical microbiology methods impairs the use of AUIC to prospectively optimize microbiological outcome. Even ignoring this limitation and using the values as they are reported, the results of this analysis suggest that AUIC targets between 72 and 275 SIT(-1) x 24 h are useful in predicting clinical outcome. (+info)A resuscitated case from asphyxia by large bronchial cast. (7/736)
A 62-year-old woman with bronchiectasis suffered from asphyxia due to a large bronchial cast that obstructed the bronchial tree. Immediate bronchoscopic suction of a bronchial cast of 17 cm in length through the intubated tube relieved the patients without any complications. Large bronchial casts appear to be rare in this century but it should be considered in patients with acute exacerbation of excessive sputa not only in patients with asthma or allergy but also in patients with respiratory tract infection. (+info)Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. (8/736)
Two hundred ninety isolates of Escherichia coli were investigated for the production of extended-spectrum beta-lactamases (ESBLs). Fourteen (4.8%) of the 290 strains were found to produce ESBLs. Each of the 14 strains produced one or two ESBLs, as follows: 10 strains produced TEM-52, 1 strain produced SHV-2a, 1 strain produced SHV-12, 1 strain produced a CMY-1-like enzyme, and 1 strain expressed SHV-2a and a CMY-1-like enzyme. Another two strains for which the MICs of ceftazidime and cefoxitin were high, were probable AmpC enzyme hyperproducers. Because of the high prevalence of TEM-52 in E. coli isolates, we further investigated the TEM-type ESBLs produced by Klebsiella pneumoniae in order to observe the distribution of TEM-52 enzymes among Enterobacteriaceae in Korea. All TEM enzymes produced by 12 strains of K. pneumoniae were identified as TEM-52. To evaluate the genetic relatedness among the organisms, ribotyping of TEM-52-producing E. coli and K. pneumoniae was performed. The ribotyping profiles of the organisms showed similar but clearly different patterns. In conclusion, TEM-52 is the most prevalent TEM-type ESBL in Korea. (+info)Pseudomonas infections are challenging to treat due to the bacteria's ability to develop resistance against antibiotics. The treatment typically involves a combination of antibiotics and other supportive therapies, such as oxygen therapy or mechanical ventilation, to manage symptoms and prevent complications. In some cases, surgical intervention may be necessary to remove infected tissue or repair damaged organs.
Melioidosis is typically acquired through contact with contaminated soil or water in tropical and subtropical regions of Asia and Africa. The bacteria can enter the body through open wounds, cuts, or through the eyes, nose, or mouth. Once inside the body, the bacteria can multiply and cause a wide range of symptoms including fever, chills, headache, muscle and joint pain, and skin lesions.
If left untreated, melioidosis can lead to serious complications such as sepsis, meningitis, and pneumonia, which can be fatal. The disease is diagnosed through a combination of physical examination, laboratory tests, and imaging studies. Treatment typically involves antibiotics, and early treatment is essential for effective management of the disease.
In addition to being an important medical condition, melioidosis is also of interest to researchers studying the bacteria that cause the disease. Burkholderia pseudomallei has been found to have a unique ability to survive in a variety of environments, including soil and water, and has been studied for its potential as a bioterrorism agent.
In summary, melioidosis is a serious bacterial infection caused by Burkholderia pseudomallei that can affect multiple organ systems and cause severe illness if left untreated. It is typically acquired through contact with contaminated soil or water in tropical and subtropical regions of Asia and Africa and is diagnosed through a combination of physical examination, laboratory tests, and imaging studies. Early treatment is essential for effective management of the disease.
Previous article'Etiology' Next article 'Esophageal Cancer'
Klebsiella Infections can occur in anyone, but certain groups of people are at higher risk, such as premature infants, people with weakened immune systems, and those with chronic medical conditions like diabetes, liver or kidney disease.
Symptoms of Klebsiella Infections include fever, chills, cough, difficulty breathing, painful urination, redness and swelling in the affected area, and in severe cases, sepsis and death.
Diagnosis of Klebsiella Infections is typically made through a combination of physical examination, medical history, and laboratory tests, such as blood cultures and urine cultures.
Treatment of Klebsiella Infections usually involves antibiotics, which can help clear the infection and prevent it from spreading. In severe cases, hospitalization may be necessary to provide appropriate care and monitoring.
Prevention of Klebsiella Infections includes good hand hygiene, proper cleaning and disinfection of equipment and surfaces, and avoiding close contact with individuals who have the infection. Vaccines are also available for certain types of Klebsiella Infections, such as pneumonia.
Complications of Klebsiella Infections can include pneumonia, urinary tract infections, bloodstream infections, and sepsis, which can lead to organ failure and death if left untreated.
Recovery from Klebsiella Infections usually occurs within a few days to a week after antibiotic treatment is started, but in severe cases, recovery may take longer and may require hospitalization and close monitoring.
In conclusion, Klebsiella Infections are a type of bacterial infection that can affect various parts of the body, and can be mild or severe. Prompt diagnosis and treatment with antibiotics are essential to prevent complications and ensure a successful recovery. Proper hygiene practices and vaccines are also important for preventing the spread of these infections.
Bronchopneumonia is a serious condition that can lead to respiratory failure and other complications if left untreated. It is important for individuals with bronchopneumonia to seek medical attention promptly if they experience any worsening symptoms or signs of infection, such as increased fever or difficulty breathing.
Bronchopneumonia can be caused by a variety of factors, including bacterial and viral infections, and can affect individuals of all ages. It is most common in young children and the elderly, as well as those with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD).
Treatment for bronchopneumonia typically involves antibiotics to treat any bacterial infections, as well as supportive care to help manage symptoms and improve lung function. In severe cases, hospitalization may be necessary to provide more intensive treatment and monitoring.
In addition to antibiotics and supportive care, other treatments for bronchopneumonia may include:
* Oxygen therapy to help increase oxygen levels in the blood
* Pain management medications to relieve chest pain and fever
* Breathing exercises and pulmonary rehabilitation to improve lung function
* Rest and relaxation to help the body recover
Prevention is key in avoiding bronchopneumonia, and this can be achieved through:
* Good hand hygiene and respiratory etiquette
* Avoiding close contact with individuals who are sick
* Getting vaccinated against pneumococcal disease and the flu
* Practicing good hygiene during travel to avoid exposure to respiratory infections.
In conclusion, bronchopneumonia is a serious condition that can be caused by a variety of factors and can affect individuals of all ages. Treatment typically involves antibiotics and supportive care, and prevention strategies include good hygiene practices and vaccination. With proper treatment and care, individuals with bronchopneumonia can recover and lead active lives.
Some common examples of bacterial infections include:
1. Urinary tract infections (UTIs)
2. Respiratory infections such as pneumonia and bronchitis
3. Skin infections such as cellulitis and abscesses
4. Bone and joint infections such as osteomyelitis
5. Infected wounds or burns
6. Sexually transmitted infections (STIs) such as chlamydia and gonorrhea
7. Food poisoning caused by bacteria such as salmonella and E. coli.
In severe cases, bacterial infections can lead to life-threatening complications such as sepsis or blood poisoning. It is important to seek medical attention if symptoms persist or worsen over time. Proper diagnosis and treatment can help prevent these complications and ensure a full recovery.
Gram-negative bacterial infections can be difficult to treat because these bacteria are resistant to many antibiotics. In addition, some gram-negative bacteria produce enzymes called beta-lactamases, which break down the penicillin ring of many antibiotics, making them ineffective against the infection.
Some common types of gram-negative bacterial infections include:
* Pneumonia
* Urinary tract infections (UTIs)
* Bloodstream infections (sepsis)
* Meningitis
* Skin and soft tissue infections
* Respiratory infections, such as bronchitis and sinusitis
Examples of gram-negative bacteria that can cause infection include:
* Escherichia coli (E. coli)
* Klebsiella pneumoniae
* Pseudomonas aeruginosa
* Acinetobacter baumannii
* Proteus mirabilis
Gram-negative bacterial infections can be diagnosed through a variety of tests, including blood cultures, urine cultures, and tissue samples. Treatment typically involves the use of broad-spectrum antibiotics, such as carbapenems or cephalosporins, which are effective against many types of gram-negative bacteria. In some cases, the infection may require hospitalization and intensive care to manage complications such as sepsis or organ failure.
Prevention of gram-negative bacterial infections includes good hand hygiene, proper use of personal protective equipment (PPE), and appropriate use of antibiotics. In healthcare settings, infection control measures such as sterilization and disinfection of equipment, and isolation precautions for patients with known gram-negative bacterial infections can help prevent the spread of these infections.
Overall, gram-negative bacterial infections are a significant public health concern, and proper diagnosis and treatment are essential to prevent complications and reduce the risk of transmission.
This condition can be caused by various factors such as genetic mutations, infections, autoimmune disorders, and certain medications. In severe cases, agranulocytosis can lead to life-threatening infections that require prompt medical treatment.
Some of the common symptoms of agranulocytosis include fever, chills, sore throat, fatigue, and recurring infections. Diagnosis is typically made through blood tests that measure the number and function of white blood cells, including granulocytes. Treatment options for agranulocytosis depend on the underlying cause, but may include antibiotics, antiviral medications, and immunoglobulin replacement therapy in severe cases.
There are different types of fever, including:
1. Pyrexia: This is the medical term for fever. It is used to describe a body temperature that is above normal, usually above 38°C (100.4°F).
2. Hyperthermia: This is a more severe form of fever, where the body temperature rises significantly above normal levels.
3. Febrile seizure: This is a seizure that occurs in children who have a high fever.
4. Remittent fever: This is a type of fever that comes and goes over a period of time.
5. Intermittent fever: This is a type of fever that recurs at regular intervals.
6. Chronic fever: This is a type of fever that persists for an extended period of time, often more than 3 weeks.
The symptoms of fever can vary depending on the underlying cause, but common symptoms include:
* Elevated body temperature
* Chills
* Sweating
* Headache
* Muscle aches
* Fatigue
* Loss of appetite
In some cases, fever can be a sign of a serious underlying condition, such as pneumonia, meningitis, or sepsis. It is important to seek medical attention if you or someone in your care has a fever, especially if it is accompanied by other symptoms such as difficulty breathing, confusion, or chest pain.
Treatment for fever depends on the underlying cause and the severity of the symptoms. In some cases, medication such as acetaminophen (paracetamol) or ibuprofen may be prescribed to help reduce the fever. It is important to follow the recommended dosage instructions carefully and to consult with a healthcare professional before giving medication to children.
In addition to medication, there are other ways to help manage fever symptoms at home. These include:
* Drinking plenty of fluids to stay hydrated
* Taking cool baths or using a cool compress to reduce body temperature
* Resting and avoiding strenuous activities
* Using over-the-counter pain relievers, such as acetaminophen (paracetamol) or ibuprofen, to help manage headache and muscle aches.
Preventive measures for fever include:
* Practicing good hygiene, such as washing your hands frequently and avoiding close contact with people who are sick
* Staying up to date on vaccinations, which can help prevent certain infections that can cause fever.
Endophthalmitis can be classified into several types based on its causes, such as:
1. Postoperative endophthalmitis: This type of endophthalmitis occurs after cataract surgery or other intraocular surgeries. It is caused by bacterial infection that enters the eye through the surgical incision.
2. Endogenous endophthalmitis: This type of endophthalmitis is caused by an infection that originates within the eye, such as from a retinal detachment or uveitis.
3. Exogenous endophthalmitis: This type of endophthalmitis is caused by an infection that enters the eye from outside, such as from a penetrating injury or a foreign object in the eye.
The symptoms of endophthalmitis can include:
1. Severe pain in the eye
2. Redness and swelling of the conjunctiva
3. Difficulty seeing or blind spots in the visual field
4. Sensitivity to light
5. Increased sensitivity to touch or pressure on the eye
6. Fever and chills
7. Swollen lymph nodes
8. Enlarged pupil
9. Clouding of the vitreous humor
If you suspect that you or someone else has endophthalmitis, it is important to seek medical attention immediately. Early diagnosis and treatment can help prevent vision loss. Treatment options for endophthalmitis may include antibiotics, vitrectomy (removal of the vitreous humor), and in some cases, removal of the affected eye.
In medicine, cross-infection refers to the transmission of an infectious agent from one individual or source to another, often through direct contact or indirect exposure. This type of transmission can occur in various settings, such as hospitals, clinics, and long-term care facilities, where patients with compromised immune systems are more susceptible to infection.
Cross-infection can occur through a variety of means, including:
1. Person-to-person contact: Direct contact with an infected individual, such as touching, hugging, or shaking hands.
2. Contaminated surfaces and objects: Touching contaminated surfaces or objects that have been touched by an infected individual, such as doorknobs, furniture, or medical equipment.
3. Airborne transmission: Inhaling droplets or aerosolized particles that contain the infectious agent, such as during coughing or sneezing.
4. Contaminated food and water: Consuming food or drinks that have been handled by an infected individual or contaminated with the infectious agent.
5. Insect vectors: Mosquitoes, ticks, or other insects can transmit infections through their bites.
Cross-infection is a significant concern in healthcare settings, as it can lead to outbreaks of nosocomial infections (infections acquired in hospitals) and can spread rapidly among patients, healthcare workers, and visitors. To prevent cross-infection, healthcare providers use strict infection control measures, such as wearing personal protective equipment (PPE), thoroughly cleaning and disinfecting surfaces, and implementing isolation precautions for infected individuals.
In summary, cross-infection refers to the transmission of an infectious agent from one individual or source to another, often through direct contact or indirect exposure in healthcare settings. Preventing cross-infection is essential to maintaining a safe and healthy environment for patients, healthcare workers, and visitors.
Ceftazidime
GSK plc
Cefotaxime
Sean P. F. Hughes
Burkholderia pseudomallei
Cefsulodin
Vancomycin
Richard Sykes (microbiologist)
Hospital-acquired pneumonia
Stenotrophomonas maltophilia
Melioidosis
Aztreonam
Septic arthritis
Akinyinka Omigbodun
Globe rupture
Anaerococcus
Bacterial morphological plasticity
Beta-lactamase
Vibrio vulnificus
Asterixis
Brevundimonas faecalis
Ceftriaxone
Antibiotic
Paul Girolami
Clostridial necrotizing enteritis
Citrobacter murliniae
Burkholderia cepacia complex
Known Unknowns
Endophthalmitis
Intravitreal injection
Ceftazidime for Injection
Ceftazidime Injection: MedlinePlus Drug Information
MedlinePlus - Search Results for: CEFTAZIDIME ANHYDROUS
CEFTAZIDIME ANHYDROUS - Books - NCBI
Ceftazidime and Avibactam - PubMed
Ceftazidime and Avibactam - PubMed
Ceftazidime-Resistant Salmonella enterica, Morocco - Volume 15, Number 10-October 2009 - Emerging Infectious Diseases journal -...
Pharmacokinetics of ceftazidime in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular...
Dynamic Emergence of Pseudomonas aeruginosa Hypermutation and Ceftazidime-Avibactam Resistance in Acute Systemic Infection |...
cefTAZidime Launches - SteriMax Inc.
CefTAZidime in: Pediatric Injectable Drugs
Acute Cholecystitis Medication: Antiemetics, Analgesics, Antibiotics
DailyMed - AVYCAZ- ceftazidime, avibactam powder, for solution
Haute Autorité de Santé - Résultat de recherche
Wholesale Ceftazidime Avibactam Aztreonam Manufacturer and Supplier, Factory Exporters | LonGoChem
Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae...
Antibiotics Tested by NARMS | NARMS | CDC
Isolate Details | Antimicrobial Resistance Isolate Bank | Antibiotic/Antimicrobial Resistance | CDC
John Bartlett's Take on Critical ID Topics: Part 2
Ginger As Antiemetic in Children With Acute Gastroenteritis
Aviane Advanced Patient Information - Drugs.com
Synergistic Activity of Three Iranian Medicinal Plants in Combination with Ceftazidime and Neomycin against Bacterial Strains...
Furosemide (Lasix) | Davis's Drug Guide
Melioidosis - Wikipedia
Global Antibacterial Drugs Market Size | Share | Industry report, 2020-2030
Publications - BPCA | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell...
Avibactam6
- Ceftazidime and Avibactam. (nih.gov)
- Ceftazidime-avibactam is acceptable in nursing mothers. (nih.gov)
- In this work, we apply genomic sequencing to 9 serially-collected P. aeruginosa isolates cultured during the course of an acute systemic infection in a single patient in which both a hypermutator phenotype and ceftazidime-avibactam (CZA) resistance rapidly emerged in vivo. (nih.gov)
- AVYCAZ 2.5g (ceftazidime and avibactam) for injection is supplied as a sterile powder for constitution in single-dose vials containing ceftazidime 2 grams (equivalent to 2.635 grams of ceftazidime pentahydrate/sodium carbonate powder) and avibactam 0.5 grams (equivalent to 0.551 grams of avibactam sodium). (nih.gov)
- Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis. (bvsalud.org)
- Ceftazidime -avibactam (CAZ-AVI) and polymyxins are considered as the last therapeutic options worldwide. (bvsalud.org)
Anhydrous2
Injection20
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection and other antibacterial drugs, ceftazidime for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (nih.gov)
- Ceftazidime for injection, USP is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. (nih.gov)
- Ceftazidime for injection, USP is a white to cream-colored crystalline powder. (nih.gov)
- Solutions of ceftazidime for injection, USP range in color from light yellow to amber, depending on the diluent and volume used. (nih.gov)
- Ceftazidime injection is in a class of medications called cephalosporin antibiotics. (medlineplus.gov)
- Antibiotics such as ceftazidime injection will not work for colds, flu, or other viral infections. (medlineplus.gov)
- Ceftazidime injection comes as a powder to be mixed with liquid and given intravenously (into a vein) or intramuscularly (into a muscle). (medlineplus.gov)
- Ceftazidime injection is also available as a premixed product to be injected intravenously. (medlineplus.gov)
- You may receive ceftazidime injection in a hospital or you may administer the medication at home. (medlineplus.gov)
- If you will be receiving ceftazidime injection at home, your healthcare provider will show you how to use the medication. (medlineplus.gov)
- You should begin to feel better during the first few days of treatment with ceftazidime injection. (medlineplus.gov)
- Take ceftazidime injection until you finish the prescription, even if you feel better. (medlineplus.gov)
- If you stop taking ceftazidime injection too soon or skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (medlineplus.gov)
- Ceftazidime injection is also sometimes used to treat patients who have a fever and are at high risk for infection because they have a low number of white blood cells, melioidosis (a serious infection that is common in places with a tropical climate), certain wound infections, and food poisoning. (medlineplus.gov)
- Also tell your doctor if you are allergic to any of the ingredients in ceftazidime injection. (medlineplus.gov)
- you should know that ceftazidime injection decreases the effectiveness of some oral contraceptives ('birth control pills). (medlineplus.gov)
- If you become pregnant while taking ceftazidime injection, call your doctor. (medlineplus.gov)
- Ceftazidime injection may cause side effects. (medlineplus.gov)
- To learn more visit the cefTAZidime for Injection product page. (sterimaxinc.com)
- For example, a 500 MG single-use vial of ceftazidime will have 'Ceftazidime 500 MG Injection' as a normalized name. (nih.gov)
Intravenous1
- [1] Those with melioidosis are treated first with an "intensive phase" course of intravenous antibiotics (most commonly ceftazidime ) followed by a several-month treatment course of co-trimoxazole . (wikipedia.org)
Meropenem2
- Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. (medscape.com)
- Klebsiella pneumoniae ( K . pneumoniae ) is the leading pathogen globally underlying cases of neonatal sepsis and is frequently resistant to antibiotic treatment regimens recommended by the World Health Organization (WHO), including first-line therapy with ampicillin and gentamicin, second-line therapy with amikacin and ceftazidime, and meropenem. (plos.org)
Penicillins1
- Isolates were resistant to penicillins and ceftazidime but were susceptible to other antimicrobial drug classes tested. (cdc.gov)
Pharmacokinetics1
- The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. (nih.gov)
Antibiotics1
- The antimicrobial effects of these plants had been reported before but synergistic effect with broad spectrum antibiotics such as ceftazidime and neomycin was an important issue that we tried to determine. (rjpharmacognosy.ir)
Sodium carbonate1
- The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. (nih.gov)
Cefotaxime1
- Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime]. (nih.gov)
Resistance2
- Isolates showed higher levels of resistance to ceftazidime (MIC 128 mg/L) than to ceftriaxone (MIC 8 mg/L). (cdc.gov)
- Development of Ceftazidime Resistance in Burkhoderia pseudomallei in a Patient Experiencing Melioidosis with Mediastinal. (annals.edu.sg)
Compounds1
- Salvia limbata is a potentially rich source of bioactive compounds with antimicrobial properties that can be used with ceftazidime and neomycin to provide a synergistic effect. (rjpharmacognosy.ir)
Doses4
- After IV administration of 500 mg and 1 g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum concentrations of 45 and 90 mcg/ mL, respectively, were achieved. (nih.gov)
- After IV infusion of 500 mg, 1 g, and 2 g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. (nih.gov)
- There was no evidence of accumulation of ceftazidime in the serum in individuals with normal renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days. (nih.gov)
- Following intramuscular (IM) administration of 500 mg and 1 g doses of ceftazidime to normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL, respectively, at approximately 1 hour. (nih.gov)
Activity2
- The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. (nih.gov)
- The fractional inhibitory concentration (FIC) results showed partial synergistic activity between S. limbata with ceftazidime and neomycin against P. aeruginosa and MRSA. (rjpharmacognosy.ir)
Effects1
- Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in breastfed infants. (nih.gov)
Hours1
- The half-life of ceftazidime in these volunteers was approximately 2 hours. (nih.gov)
Combination1
- The MIC of ceftazidime and neomycin in combination with S. limbata was reduced fourfold for each antibiotic. (rjpharmacognosy.ir)
High1
- The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine. (nih.gov)
Drug1
- Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. (nih.gov)
Cephalosporin1
- Ceftazidime injection is in a class of medications called cephalosporin antibiotics. (medlineplus.gov)
Urinary tract infe1
- On March 18, 2019, the Food and Drug Administration (FDA) extended approval for ceftazidime-avibactam to pediatric patients 3 months of age and older for the treatment of complicated intra-abdominal infections (cIAI) in combination with metronidazole and the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. (medscape.com)
Pentahydrate2
- Ceftazidime for injection, USP is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. (nih.gov)
- AVYCAZ 2.5g (ceftazidime and avibactam) for injection is supplied as a sterile powder for constitution in single-dose vials containing ceftazidime 2 grams (equivalent to 2.635 grams of ceftazidime pentahydrate/sodium carbonate powder) and avibactam 0.5 grams (equivalent to 0.551 grams of avibactam sodium). (nih.gov)
Pseudomonas1
- She was found to have persistent osteomyelitis and started on ceftazidime for a culture documented Pseudomonas aeruginosa infection. (nih.gov)
Cephalosporins1
- Cefepime and ceftazidime are cephalosporins used for the treatment of serious Gram-negative infections. (nih.gov)
CUTI1
- [ 1 ] Ceftazidime-avibactam was first approved in 2015 for adults with cIAI and cUTI, and was subsequently approved for the treatment of hospital-acquired or ventilator-associated pneumonia in February 2018. (medscape.com)
Infants4
- We identified all infants discharged from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012 who were exposed to either cefepime or ceftazidime in the first 120 days of life. (nih.gov)
- We reported clinical and laboratory adverse events occurring in infants exposed to cefepime or ceftazidime and used multivariable logistic regression to compare the odds of seizures and death between the 2 groups. (nih.gov)
- A total of 1761 infants received 13,293 days of ceftazidime, and 594 infants received 4628 days of cefepime. (nih.gov)
- Seizure was the most commonly observed clinical adverse event, occurring in 3% of ceftazidime-treated infants and 4% of cefepime-treated infants (P = 0.52). (nih.gov)
Ceftriaxone1
- Gram-negative coverage comparable to that of ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). (medscape.com)
Intravenously1
- The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. (nih.gov)
Broad-spectrum1
- Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. (nih.gov)
Clinical3
- Clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function. (bvsalud.org)
- This study was designed to analyze the clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function. (bvsalud.org)
- To sum up, ceftazidime combined with levofloxacin on patients with heart failure and pulmonary infection can improve the immune function while optimizing the clinical efficacy and cardiopulmonary function. (bvsalud.org)
Resistant1
- Isolates were resistant to penicillins and ceftazidime but were susceptible to other antimicrobial drug classes tested. (cdc.gov)
Liver1
- Still, the most likely culprit was ceftazidime, a rare cause of drug induced liver injury with very few reports in the literature. (nih.gov)
Medications1
- Due to rapid identification, all medications with potential hepatotoxicity, including ceftazidime, were discontinued and the LFTs promptly returned to baseline over 3 days. (nih.gov)
Patients1
- Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function. (nih.gov)
Route1
- The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. (nih.gov)
Search1
- Your search for CEFTAZIDIME ANHYDROUS did not return any results. (nih.gov)
Total1
- The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. (nih.gov)